TSX/EPRX (TSX/EPRX)

Toronto Stock Exchange: TSX/EPRX · CAD

CA$10.3

+0.33 (+3.3%)· Recorded snapshot

Market cap	679.5M
Net income (ttm)	-74.8M
EPS (ttm)	-CA$1.42
Shares out	65.9M
Volume	66,474
Beta	1.21

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -74.8M
EPS (ttm): -CA$1.42
Market cap: 679.5M

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-66.7

P25 n/aP50 n/aP75 n/a

ROIC-46.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All TSX/EPRX indicators

Market & fundamental data

Available fields

155

Groups with data

Currency

USD

Showing 155 of 155 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	CAD
Country	Canada
Country code	CA
Earnings date	2026-11-05
Employees	49
Employees change	16
Employees growth	48.48%
Enterprise value	CAD 532M
Exchange	Toronto Stock Exchange
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	December
Founded	2011
Industry	Biotechnology
Is primary listing	Yes
ISIN number	CA29842P1053
Last earnings date	2025-11-07
Last refreshed	2026-10-28
Market cap	CAD 679.5M
Next earnings date	2026-11-05
Price	CAD 10.31
Price currency	CAD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	tsx/EPRX
Website	https://www.eupraxiapharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-13.74%
FCF / EV yield	-10.64%
FCF yield	-8.25%
P/B ratio	3.57x
Price / tangible book value	4.55x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
ROA	-43.66%
ROA (5Y)	-61.98%
ROCE	-43.47%
ROE	-66.7%
ROIC	-46.8%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	CAD -1.1M
Depreciation and amortization	CAD 336,498
EBIT	CAD -81.1M
EBITDA	CAD -80.8M
EPS	CAD -1.42
FCF per share	CAD -0.82
Financing cash flow	CAD 215.1M
Free cash flow	CAD -54.3M
Free cash flow minus SBC	CAD -70.5M
Income taxes	CAD 78,108
Investing cash flow	CAD -114.3M
Net cash flow	CAD 46.4M
Net income	CAD -74.8M
Operating cash flow minus SBC	CAD -69.4M
Operating income	CAD -81.1M
Stock-based compensation	CAD 16.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	CAD 2.21
Debt / equity	0.01
Long-term assets	CAD 6.4M
Long-term liabilities	CAD 2.5M
Net cash (debt)	CAD 187.2M
Net cash / market cap	28.46%
Net cash growth	568.09%
Net debt / equity	-1.02
Piotroski F-Score	2
Property, plant and equipment	CAD 4.3M
Shareholders' equity	CAD 184.1M
Tangible book value	CAD 144.5M
Tangible book value per share	CAD 2.21
Total assets	CAD 198.7M
Total cash	CAD 189.8M
Total debt	CAD 2.6M
Total liabilities	CAD 14.5M
WACC	10.89%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	CAD 192.3M
Current liabilities	CAD 12M
Current ratio	16
Net working capital	CAD -7.5M
Quick ratio	15.71
Working capital	CAD 182.1M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-47.8%
Shareholder yield	-47.8%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	CAD 9.83
1D price change	3.31%
1M price change	-10.26%
1M total return	-10.26%
1W price change	-5.32%
1W total return	-5.32%
1Y price change	34.08%
1Y return CAGR	34.11%
1Y total return	34.08%
20-day SMA	CAD 10.40
200-day SMA	CAD 10.18
3M price change	16.13%
3M total return	16.13%
3Y price change	81.25%
3Y return CAGR	21.92%
3Y total return	81.25%
50-day SMA	CAD 10.61
50-day SMA vs 200-day SMA	50over200
52-week high	CAD 13.08
52-week high date	2026-09-30
52-week low	CAD 7.35
52-week low date	2025-11-07
5Y price change	341.3%
5Y return CAGR	34.58%
5Y total return	341.3%
6M price change	2.84%
6M total return	2.84%
All-time high	CAD 13.08
All-time high date	2026-09-30
All-time low	CAD 0.80
All-time low date	2022-05-10
Average true range (ATR)	CAD 0.68
Average volume	107.7K
Beta (1Y)	1.13
Beta (2Y)	1
Beta (5Y)	1.21
Change from 52-week high	-21.18%
Change from 52-week low	40.27%
Change from all-time high	-22.4%
Change from all-time low	1,168.75%
Change from open	4.99%
Day's gap	-1.6%
Dollar volume	CAD 685,347
High price	CAD 10.34
Low price	CAD 9.71
Monthly RSI	56.7
Open price	CAD 9.82
Position in 52-week range	95.24%
Previous close	CAD 9.98
Price vs 150-day SMA	3.31%
Price vs 20-day SMA	-2.44%
Price vs 200-day SMA	-0.32%
Price vs 50-day SMA	-4.34%
Relative volume	0.62
RSI	47.61
Sharpe ratio	0.71
Sharpe ratio (3Y)	0.56
Sharpe ratio (5Y)	0.68
Sortino ratio	1.23
Sortino ratio (3Y)	0.96
Sortino ratio (5Y)	1.15
Volume	66.5K
Weekly RSI	51.29
YTD price change	-1.65%
YTD total return	-1.65%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	55.7M
Shares change (QoQ)	16.77%
Shares change (YoY)	47.8%
Shares held by insiders	15.53%
Shares held by institutions	43.7%
Shares outstanding	65.9M

Deeper analysis on TSX/EPRX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this TSX/EPRX report

Is a complete TSX/EPRX research report available?

No complete published report is available for tsx/EPRX (TSX/EPRX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

TSX/EPRX (TSX/EPRX)

Price

Financial snapshot

Fair-value bridge

Latest news · TSX/EPRX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All TSX/EPRX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on TSX/EPRX

Frequently asked questions